Zelegent expands to OSA therapeutics with MISH platform acquisition
Category: #health  By Pankaj Singh  Date: 2019-09-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Zelegent expands to OSA therapeutics with MISH platform acquisition
  • MISH Technology stands for Minimally Invasive Suspension of the Hyoid and is a novel pre-clinical product line meant to treat obstructive sleep apnea (OSA).
  • MISH is relatively less invasive when compared with presently used hyoid suspension products since it does not require any external neck incision; a needle puncture site.

Zelegent, a U.S. based company involved in manufacturing of innovative equipment for otolaryngologist sleep specialists and whose Elevo® Set is currently being sold to physicians across the U.S., reportedly announced the acquisition of rights to a novel pre-clinical product line meant to treat obstructive sleep apnea (OSA).

The Elevo Snoring Intervention Set, existing product line of the company, is utilized by physicians for the treatment of primary snoring, particularly known as disruptive snoring among patients without OSA. The MISH technology platform is developed with the intention of providing an alternative to technologies currently in operation for treating OSA.

MISH stands for Minimally Invasive Suspension of the Hyoid. Hyoid bone suspension is an existing procedure for the OSA treatment which carries its unique reimbursement code. MISH is relatively less invasive when compared with presently operating hyoid suspension products, since it does not have any external neck incision; a needle puncture site.

Zelegent procured worldwide exclusive rights to MISH from Valam Corporation. Particular terms of the procurement have not been disclosed yet, except that the acquisition agreement includes both royalty and equity.

Chief Executive Officer at Zelegent, Alexander K. Arrow, MD stated that unlike currently running hyoid suspension devices, MISH process does not require a permanent implant. Arrow added that the components needed to suspend hyoid bone in the MISH procedure are entirely resorbable following implantation, further making the MISH process consistent with the theme of Elevo Set, Zelegent’s first product line.

Zelegent provides the Elevo Set product, via exclusive marketing, distribution and sales tie-up with Cook Medical.

Source credit: https://www.globenewswire.com/news-release/2019/09/15/1915627/0/en/Zelegent-Acquires-MISH-Technology-Platform-Extending-Product-Pipeline-into-Obstructive-Sleep-Apnea-Therapeutics.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...